CALA · Calithera Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | $9.75M | - | - | $25.95M | $25.95M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $28.53M | $71.02M | $71.02M | $76.29M | $66.19M | $43.11M |
| SG&A | $13.54M | $20.85M | $20.37M | $16.61M | $13.34M | $12.53M |
| Total Operating Expenses | $42.07M | $125.18M | $91.39M | $92.89M | $79.53M | $55.64M |
| D&A | $300.0K | $300.0K | $364.0K | $479.0K | $505.0K | $365.0K |
| Operating Income | ($42.07M) | ($115.43M) | ($91.39M) | ($92.89M) | ($57.28M) | ($29.69M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($39.65M) | ($115.09M) | ($90.14M) | ($89.86M) | ($54.63M) | ($27.83M) |
| EPS - Basic | ($26.20) | - | - | - | - | - |
| EPS - Diluted | ($26.20) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.45M | $59.54M | $107.15M | $60.44M | $51.06M | $48.48M |
| Accounts Receivable | - | - | $1.54M | $482.0K | $2.00M | $1.14M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $732.0K | $3.65M | $1.99M | $2.05M | $1.25M | $1.07M |
| Current Assets | $26.62M | $61.45M | $118.70M | $159.80M | $140.25M | $167.67M |
| Total Assets | $28.68M | $64.76M | $125.59M | $168.77M | $142.72M | $192.46M |
| Current Liabilities | $7.39M | $14.01M | $18.40M | $19.62M | $14.88M | $39.03M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $8.28M | $15.67M | $23.22M | $26.34M | $16.01M | $42.15M |
| Stockholders' Equity | $20.39M | $8.38M | $102.37M | $142.43M | $126.71M | $150.31M |
| Retained Earnings | ($512.62M) | ($491.33M) | ($376.24M) | ($286.10M) | ($196.17M) | ($150.33M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($43.61M) | ($66.30M) | ($84.31M) | ($78.75M) | ($31.02M) | $13.75M |
| Investing Cash Flow | ($133.0K) | $7.85M | $88.96M | ($10.78M) | $23.70M | ($98.83M) |
| Financing Cash Flow | $9.65M | $10.67M | $42.06M | $98.91M | $11.82M | $122.95M |
| CapEx | $133.0K | $147.0K | $61.0K | $7.0K | $214.0K | $1.23M |
| Free Cash Flow | ($43.74M) | ($66.45M) | ($84.37M) | ($78.75M) | ($31.24M) | $12.52M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | -1183.9% | - | - | -220.7% | -114.4% |
| EBITDA margin | - | -1180.9% | - | - | -218.7% | -113.0% |
| Net margin | - | -1180.4% | - | - | -210.5% | -107.2% |
| Free cash flow margin | - | -681.5% | - | - | -120.4% | 48.2% |
| FCF / Net income | 1.10 | 0.58 | 0.94 | 0.88 | 0.57 | -0.45 |
| R&D / Revenue | - | 728.4% | - | - | 255.0% | 166.1% |
| SG&A / Revenue | - | 213.9% | - | - | 51.4% | 48.3% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -138.3% | -177.7% | -71.8% | -53.2% | -38.3% | -14.5% |
| Return on equity | -194.4% | -1373.0% | -88.0% | -63.1% | -43.1% | -18.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.60 | 4.39 | 6.45 | 8.14 | 9.42 | 4.30 |
| Quick ratio | 3.60 | 4.39 | 6.45 | 8.14 | 9.42 | 4.30 |
| Cash ratio | 3.44 | 4.25 | 5.82 | 3.08 | 3.43 | 1.24 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.41 | 7.73 | 1.23 | 1.18 | 1.13 | 1.28 |
| Liabilities / Assets | 0.29 | 0.24 | 0.18 | 0.16 | 0.11 | 0.22 |
| Efficiency | ||||||
| Asset turnover | - | 0.15 | - | - | 0.18 | 0.13 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 28d | 16d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.6x | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | 0.0% | - |
| Revenue CAGR (3y) | - | -27.8% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 63.6% | -26.3% | 1.6% | -62.2% | -93.0% | 22.6% |
| Net income growth (YoY) | 65.5% | -27.7% | -0.3% | -64.5% | -96.3% | 26.8% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 34.2% | 21.2% | -7.1% | -152.1% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 143.3% | -91.8% | -28.1% | 12.4% | -15.7% | 201.2% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Calithera Biosciences against the 5 most active filers in the same SIC group.